Clinical Trials vs. Legal Access Programs: What's the Difference?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Patients, clinicians, researchers, and health-adjacent founders who want to understand the two main legal pathways through which someone in the United States can access a psychedelic today — and how those pathways differ in purpose, structure, rights, cost, and what they can and cannot offer.

The short answer

Two distinct legal frameworks currently permit access to psychedelics in the United States. The first is the clinical trial system, a federally regulated research pathway governed by the FDA and DEA that operates under Investigational New Drug Applications and requires IRB oversight, strict eligibility criteria, and informed consent under 21 CFR Part 50. The second is the state-licensed access program, which currently exists in Oregon, Colorado, and New Mexico, and permits supervised psychedelic sessions for adults under state law without any requirement to participate in research. These two frameworks have different legal foundations, different purposes, different protections, and different practical consequences for participants and providers. Conflating them creates real confusion about what is actually available, to whom, and what it means to take part.

What a clinical trial is

A clinical trial is a federally authorized research study testing whether an investigational drug is safe and effective. For psychedelics — which remain Schedule I under the Controlled Substances Act — running a clinical trial requires two parallel authorizations.

The first is an Investigational New Drug Application (IND) from the FDA. Under 21 CFR Part 312, a sponsor must submit a clinical protocol, an investigator brochure, and chemistry, manufacturing, and controls (CMC) data before enrolling any participants. After submission, the FDA has 30 calendar days to review the IND. If the agency does not issue a clinical hold within that window, the study may proceed. The FDA can also issue a partial or complete clinical hold at any point if it determines that participants would be exposed to unreasonable and significant risk.

The second authorization is a Schedule I researcher registration from the DEA. Because classical psychedelics have no currently accepted medical use under federal law, possessing or using them — even in a supervised research context — requires specific DEA registration for the research site, strict storage and security protocols, and detailed record-keeping. The IND and the DEA registration are separate requirements and must both be in place before a trial begins.

Every trial also requires review and approval by an Institutional Review Board (IRB), an independent committee that evaluates the ethics and safety of the study protocol before participants are enrolled and monitors it on an ongoing basis.

What clinical trial participation actually involves

Participants in a psychedelic clinical trial are research subjects, not patients receiving treatment. The distinction carries legal and practical weight.

Under 21 CFR Part 50, informed consent is required before enrollment. The consent process must cover the purpose of the research, foreseeable risks and discomforts, anticipated benefits, available alternatives, how confidentiality will be maintained, and the voluntary nature of participation. Importantly, the consent document must inform participants that they may discontinue participation at any time without penalty or loss of benefits to which they are otherwise entitled.

Eligibility criteria in psychedelic trials are typically strict. Most studies exclude people with personal or family histories of psychotic or bipolar I disorders. Cardiovascular conditions — particularly uncontrolled hypertension — are common exclusion criteria given the cardiovascular effects of several psychedelic compounds. Most trials have historically required participants to taper off SSRIs and other serotonergic medications before enrolling, because these drugs act on the same pathways as psilocybin and MDMA and could blunt effects or create unpredictable interactions.

Participants may be assigned to receive a placebo rather than the active compound. In a double-blind trial, neither participant nor researcher knows which arm a participant is in during the study period. As the PMC research on psychedelic trial design notes, many participants are disappointed — sometimes to the point of dropping out — when they learn they received placebo, even after being told this probability exists.

Clinical trials are generally free to participants. Travel costs and time burdens may be significant, however. Studies typically require multiple pre-enrollment screening visits, medication washout periods, preparation sessions, one or more dosing sessions, and follow-up assessments over weeks or months. A full study commitment can run six months or longer.

The drug used in a clinical trial is an investigational product — it is not commercially available and its safety and efficacy have not been established to FDA’s standard. Participation is research, and the trial may or may not produce a result that benefits the individual participant.

What a state-licensed access program is

Oregon, Colorado, and New Mexico have each created state-law frameworks that permit adults to access psilocybin services through licensed facilities and licensed facilitators, without any requirement to participate in research, without a prescription, and without a clinical diagnosis.

Oregon’s program operates under the Oregon Psilocybin Services Act (Ballot Measure 109, approved November 2020) and is administered by the Oregon Health Authority. Adults 21 and older — including non-residents — can participate by contacting a licensed service center, completing a preparation session with a licensed facilitator, attending an administration session at the center, and remaining on-site for the duration of the experience. A follow-up integration session is optional. Facilitators are not required to have mental health credentials but must complete a state-approved training program and hold a state license.

Colorado’s program operates under Proposition 122 (approved November 2022) and is administered by the Department of Regulatory Agencies. Licensed healing centers may administer psilocybin and psilocin to adults 21 and older. Colorado’s model also permits a clinical facilitator track, which allows licensed mental and medical health professionals to integrate psilocybin services into their existing practice settings subject to additional requirements. Facilitator licensing began in December 2024. Healing centers began operating as the regulatory infrastructure continued rolling out through 2025.

New Mexico enacted a therapeutic psilocybin program in April 2025, creating a third state-law access pathway for patients with qualifying conditions under the supervision of a licensed healthcare provider.

All three programs operate under state law only. None provide protection from federal prosecution under the Controlled Substances Act. The facilities, facilitators, and participants in these programs handle a Schedule I substance every day without federal authorization of the kind a clinical trial IND provides.

The key differences

Purpose. A clinical trial exists to generate scientific evidence about a drug’s safety and efficacy for eventual FDA approval. A state access program exists to provide supervised access to people who want it now, under state law, without waiting for federal approval.

Eligibility. Clinical trials apply strict inclusion and exclusion criteria determined by the study protocol and approved by the IRB. State access programs generally require only that the participant is 21 or older. Oregon and Colorado do not require a diagnosis, a referral, or a physician’s involvement.

What you receive. In a clinical trial, the substance is an investigational drug administered under a research protocol. You may receive placebo. In a state access program, you receive psilocybin produced by a state-licensed cultivator and administered by a licensed facilitator. There is no placebo.

Cost. Clinical trials are free to participants. Oregon sessions typically cost between $1,000 and $3,000, paid out of pocket, with insurance coverage not available. Colorado’s program is expected to offer some sliding-scale pricing as more centers open.

Federal legal protection. Clinical trial participants and their research sites operate under a federal IND, which authorizes possession and administration of Schedule I substances within the study’s scope. State access program participants and facilities have no federal authorization. They are protected from state prosecution within the regulated framework but remain exposed to federal law.

Data collection. Clinical trials collect data on participants and contribute to the body of evidence the FDA will use to evaluate future drug applications. State access programs are not required to generate or report clinical outcome data, though some researchers have conducted observational studies alongside Oregon’s program with participant consent.

Provider qualifications. Clinical trial staff are required to meet qualifications reviewed by the IRB and FDA; therapists involved in psychedelic-assisted therapy trials may need specialized training in the therapeutic model being studied. State access program facilitators must complete state-required training but need not hold mental health licenses in Oregon; Colorado’s clinical facilitator track requires existing healthcare credentials.

What neither pathway is

Neither clinical trials nor state access programs provide access to MDMA. MDMA remains Schedule I with no state-regulated program and no open trial actively enrolling participants in a route toward near-term approval. Neither pathway provides access to ibogaine, DMT, or mescaline in any regulated licensed setting in the United States at this time.

Neither pathway creates a prescription. Even in state access programs, the substance is not prescribed by a physician. Even in clinical trials, the IND structure is a research authorization, not a prescription framework.

Neither pathway guarantees a therapeutic outcome. Clinical trials are designed to measure outcomes across populations; individual participants may or may not benefit. State access programs create access to a supervised experience but do not deliver treatment in the medical sense — facilitators are not diagnosing conditions or providing psychotherapy.

Common mistakes and misconceptions

“I can join a clinical trial and get access to psilocybin pretty easily.” Clinical trial eligibility is narrow, geography-dependent, time-intensive, and often requires medication changes. Access through a trial is real but conditional.

“Oregon’s program is basically a clinical trial.” Oregon’s program and clinical trials have almost nothing in common structurally. One is a state-licensed commercial service operating under state law. The other is federally authorized research under an IND. The substances, the protections, the purpose, and the legal frameworks are all different.

“If I participate in a state access program, I’m contributing to research that will help get psilocybin approved.” State access program sessions are not clinical data. Observational studies conducted alongside these programs contribute to the literature, but participation in a licensed service center session does not constitute clinical trial participation and does not generate data that the FDA would count toward an NDA.

“Clinical trials are safer because they’re regulated.” Clinical trials have more extensive federal oversight. State programs have licensed facilitators, training requirements, and on-site safety protocols. Neither guarantee absence of harm — both require participants to make an informed decision about risk.

When you should speak with a lawyer

You should speak with a lawyer if:

You are a clinician or researcher who wants to conduct psychedelic research and wants to understand the IND and DEA registration requirements
You are a licensed mental health professional considering incorporating psilocybin services into your practice under Colorado’s clinical facilitator track and want to understand what that means for your license
You are a patient who experienced harm in either a clinical trial or a state access program and want to understand your rights
You are building a business in the psychedelic access space and need to understand which framework — state access, clinical research, or something else — applies to what you are doing

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.